$32.39
4.48% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US45258D1054
Symbol
IMCR
Sector
Industry

Immunocore Holdings plc - ADR Stock price

$32.39
+2.98 10.13% 1M
-0.03 0.09% 6M
+2.89 9.80% YTD
-20.76 39.06% 1Y
+2.18 7.22% 3Y
+6.39 24.58% 5Y
+6.39 24.58% 10Y
Nasdaq, Closing price Tue, May 20 2025
+1.39 4.48%
ISIN
US45258D1054
Symbol
IMCR
Sector
Industry

Key metrics

Market capitalization $1.63b
Enterprise Value $1.22b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 46.93
EV/Sales (TTM) EV/Sales 3.66
P/S ratio (TTM) P/S ratio 4.87
P/B ratio (TTM) P/B ratio 4.32
Revenue growth (TTM) Revenue growth 25.50%
Revenue (TTM) Revenue $334.07m
EBIT (operating result TTM) EBIT $-47.53m
Free Cash Flow (TTM) Free Cash Flow $26.05m
Cash position $837.03m
EPS (TTM) EPS $-0.44
P/E forward negative
P/S forward 4.35
EV/Sales forward 3.27
Short interest 21.84%
Show more

Is Immunocore Holdings plc - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Immunocore Holdings plc - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Immunocore Holdings plc - ADR forecast:

13x Buy
76%
3x Hold
18%
1x Sell
6%

Analyst Opinions

17 Analysts have issued a Immunocore Holdings plc - ADR forecast:

Buy
76%
Hold
18%
Sell
6%

Financial data from Immunocore Holdings plc - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
334 334
26% 26%
100%
- Direct Costs 7.37 7.37
28% 28%
2%
327 327
23% 23%
98%
- Selling and Administrative Expenses 149 149
2% 2%
45%
- Research and Development Expense 221 221
23% 23%
66%
-43 -43
35% 35%
-13%
- Depreciation and Amortization 4.05 4.05
-
1%
EBIT (Operating Income) EBIT -48 -48
32% 32%
-14%
Net Profit -21 -21
64% 64%
-6%

In millions USD.

Don't miss a Thing! We will send you all news about Immunocore Holdings plc - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunocore Holdings plc - ADR Stock News

Neutral
GlobeNewsWire
14 days ago
Immunocore reports first quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On track for dose selection in Phase 3 PRISM-MEL-301 trial in 2H 2025 Initial multiple ascending dose data for HIV functional cure candidate pre...
Neutral
GlobeNewsWire
about 2 months ago
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.
Neutral
24/7 Wall Street
about 2 months ago
After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have high expectations.
More Immunocore Holdings plc - ADR News

Company Profile

Immunocore Holdings Plc operates as a holding company. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.

Head office United Kingdom
CEO Bahija Jallal
Employees 493
Founded 2021
Website immunocore.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today